NYSE:SNY - Sanofi Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $41.33 -0.82 (-1.95 %) (As of 02/22/2019 09:02 AM ET)Previous Close$42.15Today's Range$41.2550 - $41.6752-Week Range$37.43 - $45.62Volume1.33 million shsAverage Volume911,245 shsMarket Capitalization$103.66 billionP/E Ratio13.20Dividend Yield2.85%Beta0.67 ProfileDiscussionAnalyst RatingsChartDividendEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Sanofi provides therapeutic solutions. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; Aubagio, an immunomodulatory; and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for cancers; Eloxatin, an agent for colorectal cancer; Thymoglobulin, an immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Dupixent for atopic dermatitis; Kevzara for rheumatoid arthritis; Lantus, Toujeo, Apidra, and Insuman insulins; Amaryl, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; Admelog/Insulin lispro insulin; Praluent, a cholesterol-lowering drug; and Multaq, an anti-arrhythmic drug for atrial fibrillation. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for osteoarthritis; Stilnox for insomnia; and Allegra for seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. Sanofi has strategic alliance with Sensile Medical Ltd.; collaboration with Evotec AG; and partnership with REVOLUTION Medicines, Inc. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France. Receive SNY News and Ratings via Email Sign-up to receive the latest news and ratings for SNY and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:SNY Previous Symbol CUSIPN/A CIK1121404 Webwww.sanofi.com Phone33-1-53-77-44-00Debt Debt-to-Equity Ratio0.40 Current Ratio1.22 Quick Ratio0.85Price-To-Earnings Trailing P/E Ratio13.20 Forward P/E Ratio13.33 P/E Growth2.41 Sales & Book Value Annual Sales$39.60 billion Price / Sales2.62 Cash Flow$4.5418 per share Price / Cash Flow9.10 Book Value$26.11 per share Price / Book1.58Profitability EPS (Most Recent Fiscal Year)$3.13 Net Income$4.28 billion Net Margins12.20% Return on Equity18.18% Return on Assets9.78%Miscellaneous Employees106,566 Outstanding Shares2,508,088,000Market Cap$103.66 billion Next Earnings Date4/26/2019 (Estimated) OptionableOptionable Sanofi (NYSE:SNY) Frequently Asked Questions What is Sanofi's stock symbol? Sanofi trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNY." How were Sanofi's earnings last quarter? Sanofi SA (NYSE:SNY) posted its quarterly earnings data on Thursday, February, 7th. The company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.62 by $0.01. The firm had revenue of $9 billion for the quarter, compared to the consensus estimate of $9 billion. Sanofi had a return on equity of 18.18% and a net margin of 12.20%. The business's revenue for the quarter was up 3.5% compared to the same quarter last year. During the same quarter last year, the company earned $1.06 earnings per share. View Sanofi's Earnings History. When is Sanofi's next earnings date? Sanofi is scheduled to release their next quarterly earnings announcement on Friday, April 26th 2019. View Earnings Estimates for Sanofi. What guidance has Sanofi issued on next quarter's earnings? Sanofi issued an update on its FY 2019 earnings guidance on Thursday, February, 7th. The company provided earnings per share guidance of $6.43-6.61 for the period. What price target have analysts set for SNY? 13 brokers have issued 1 year target prices for Sanofi's shares. Their forecasts range from $50.00 to $55.00. On average, they expect Sanofi's stock price to reach $52.50 in the next year. This suggests a possible upside of 27.0% from the stock's current price. View Analyst Price Targets for Sanofi. What is the consensus analysts' recommendation for Sanofi? 13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sanofi in the last year. There are currently 6 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Sanofi. Has Sanofi been receiving favorable news coverage? Headlines about SNY stock have been trending somewhat positive on Friday, according to InfoTrie Sentiment. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Sanofi earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave headlines about the company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the near future. Who are some of Sanofi's key competitors? Some companies that are related to Sanofi include Johnson & Johnson (JNJ), Pfizer (PFE), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Bayer (BAYRY), Celgene (CELG) and Shire (SHPG). What other stocks do shareholders of Sanofi own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sanofi investors own include Johnson & Johnson (JNJ), Gilead Sciences (GILD), General Electric (GE), AT&T (T), Bank of America (BAC), Pfizer (PFE), Merck & Co., Inc. (MRK), Exxon Mobil (XOM), Alibaba Group (BABA) and Cisco Systems (CSCO). Who are Sanofi's key executives? Sanofi's management team includes the folowing people: Mr. Olivier Brandicourt, CEO & Director (Age 62)Mr. Jean-Baptiste Chasseloup de Chatillon, Exec. VP & CFO (Age 53)Mr. Laurent Gilhodes, Principal Accounting Officer and VP of Corp. AccountingMr. Bruno Ménard, Chief Information officerMr. George Grofik, Head of Investor Relations Who are Sanofi's major shareholders? Sanofi's stock is owned by many different of retail and institutional investors. Top institutional investors include Barrow Hanley Mewhinney & Strauss LLC (0.90%), Fisher Asset Management LLC (0.64%), Bank of America Corp DE (0.15%), Macquarie Group Ltd. (0.13%), BlackRock Inc. (0.10%) and Brandes Investment Partners LP (0.09%). View Institutional Ownership Trends for Sanofi. Which institutional investors are selling Sanofi stock? SNY stock was sold by a variety of institutional investors in the last quarter, including Bank of America Corp DE, BlackRock Inc., Tocqueville Asset Management L.P., Brandes Investment Partners LP, Renaissance Group LLC, Mondrian Investment Partners LTD, Macquarie Group Ltd. and Freestone Capital Holdings LLC. View Insider Buying and Selling for Sanofi. Which institutional investors are buying Sanofi stock? SNY stock was purchased by a variety of institutional investors in the last quarter, including Barrow Hanley Mewhinney & Strauss LLC, United Services Automobile Association, Fisher Asset Management LLC, Bank of Montreal Can, Aviance Capital Management LLC, Oregon Public Employees Retirement Fund, Edge Capital Group LLC and Chartwell Investment Partners LLC. View Insider Buying and Selling for Sanofi. How do I buy shares of Sanofi? Shares of SNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Sanofi's stock price today? One share of SNY stock can currently be purchased for approximately $41.33. How big of a company is Sanofi? Sanofi has a market capitalization of $103.66 billion and generates $39.60 billion in revenue each year. The company earns $4.28 billion in net income (profit) each year or $3.13 on an earnings per share basis. Sanofi employs 106,566 workers across the globe. What is Sanofi's official website? The official website for Sanofi is http://www.sanofi.com. How can I contact Sanofi? Sanofi's mailing address is 54 RUE LA BOETIE, PARIS I0, 75008. The company can be reached via phone at 33-1-53-77-44-00 or via email at [email protected] MarketBeat Community Rating for Sanofi (NYSE SNY)Community Ranking: 2.2 out of 5 ( )Outperform Votes: 389 (Vote Outperform)Underperform Votes: 494 (Vote Underperform)Total Votes: 883MarketBeat's community ratings are surveys of what our community members think about Sanofi and other stocks. Vote "Outperform" if you believe SNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SNY will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2019 by MarketBeat.com StaffFeatured Article: What is a short straddle?